journal article·2020-06

Immunoaffinity biosensor for neurofilament light chain detection and its use in Parkinson's diagnosis

Erdoğan Özgür, Handan Uzunçakmak Uyanık, Serap Şenel, Lokman Uzun

Publisher page

Abstract

Abstract Neurofilament light chain (NfL) has been classified as one of the most prominent biomarkers for identification of Parkinson's disease that is manifested by loss of dopaminergic neurons in the gray matter of the brain with the formation of cytoplasmic inclusion bodies in the brain tissue. Novel biosensors are needed for diagnosis of Parkinson's disease as well as monitoring of the treatment process. So, the concentration of NfL in cerebrospinal fluid has been reported to be useful in distinguishing Parkinson's disease from atypical Parkinson's syndromes. For this purpose, an electrochemical immunoaffinity biosensor having limit of detection (LOD), and limit of quantitation (LOQ) as 5.21 ng/L and 15.79 ng/L has been developed for the determination of NfL concentration. In this study, glycidyl methacrylate (GMA) functional monomer was used to form thin polymeric films on the electrode surface and the anti-NfL antibody was immobilized via covalent linkage with GMA as a biorecognition agent.
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Parkinson's Disease Mechanisms and Treatments · RNA regulation and disease · Neurological disorders and treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (25)

Show source-provided references
1. Price · J. Neuroimmune. Pharmacol. · 2013 · 8 · 114710.1007/s11481-013-9491-3 ↗
2. Blennow · Nat. Rev. Neurol. · 2010 · 6 · 13110.1038/nrneurol.2010.4 ↗
3. C.E. Teunissen, C. Verheul, E.A.J. Willemse, Handbook of Clinical Neurology: Cerebrospinal Fluid in Neurologic Disorders, 3rd series, Vol. 146 (Eds.: F. Deisenhammer, C. E. Teunissen, H. Tumani), Elsevier, pp. 3-20, 2018.
4. Gaetani · Alzheimers Res. Ther. · 2018 · 10 · 810.1186/s13195-018-0339-1 ↗
5. Lun · Nat. Rev. Neurosci. · 2015 · 16 · 44510.1038/nrn3921 ↗
6. Sako · J. Neurol. Sci. · 2015 · 352 · 8410.1016/j.jns.2015.03.041 ↗
7. Zetterberg · Neuron · 2016 · 91 · 110.1016/j.neuron.2016.06.030 ↗
8. Van Geel · J. Immunol. Methods · 2005 · 296 · 17910.1016/j.jim.2004.11.015 ↗
9. Constantinescu · Parkinsonism. Relat. Disord. · 2009 · 15 · 20510.1016/j.parkreldis.2008.05.001 ↗
10. Holmberg · Parkinsonism. Relat. Disord. · 2001 · 8 · 2310.1016/S1353-8020(00)00083-3 ↗
11. Abdo · Neurobiol. Aging. · 2007 · 28 · 74210.1016/j.neurobiolaging.2006.03.010 ↗
12. Constantinescu · Parkinsonism Relat Disord. · 2010 · 16 · 14210.1016/j.parkreldis.2009.07.007 ↗
13. Magdalinou · J. Neurol. Neurosurg. Psychiatry. · 2015 · 86 · 124010.1136/jnnp-2014-309562 ↗
14. Parkinson's disease and parkinsonism: neuropathology10.1101/cshperspect.a009258 ↗
15. Schrag · Lancet · 1999 · 354 · 177110.1016/S0140-6736(99)04137-9 ↗
16. Holmberg · Disord. · 1998 · 13 · 7010.1002/mds.870130116 ↗
17. Hall · Arch. Neurol. · 2012 · 69 · 144510.1001/archneurol.2012.1654 ↗
18. Karlsson · J. Neurochem. · 1989 · 53 · 75910.1111/j.1471-4159.1989.tb11770.x ↗
19. Rosengren · J. Neurochem. · 1996 · 67 · 201310.1046/j.1471-4159.1996.67052013.x ↗
20. Norgren · Brain. Res. · 2003 · 987 · 2510.1016/S0006-8993(03)03219-0 ↗
21. Hür · Lett. Org. Chem. · 2007 · 4 · 58510.2174/157017807782795556 ↗
22. Özgür · Sens. Actuator B-Chem. · 2017 · 251 · 67410.1016/j.snb.2017.05.030 ↗
23. Xu · Biomacromolecules · 2005 · 6 · 101210.1021/bm0493178 ↗
24. Jiang · Chem. Soc. Rev. · 2013 · 42 · 339410.1039/c2cs35453e ↗
25. J. Wang, Analytical electrochemistry, 3rd ed., (Eds.: J. Wang), Wiley-VCH, Weinheim, pp. 29-67, 2006.